DescriptionAptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. CG026806 (CG-806), its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL).
Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.
Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.
A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.
What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.
A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.
Latest Press Releases
|Period||Period Low||Period High||Performance|
|1-Month|| 3.21 +1.87% increase |
| 4.30 -23.95% decrease |
| -0.91 (-21.77%) decrease |
|3-Month|| 3.21 +1.87% increase |
| 7.14 -54.20% decrease |
| -3.63 (-52.61%) decrease |
|52-Week|| 3.21 +1.87% increase |
| 9.40 -65.21% decrease |
| -3.28 (-50.08%) decrease |